Retatrutide, this dual GLP-1 and GIP receptor agonist, is presently not accessible widely offered in the United Kingdom . While studies are ongoing, authorized distribution dates remain unknown. Patients interested in discovering more should speak with their healthcare provider about future options and stay updated of further announcements regar… Read More